Valuation: Shanghai Rightongene Biotechnology Co., Ltd.

Market Cap 1.14B 169M 147M 137M 126M 237M 16.12B 241M 1.61B 633M 8.04B 635M 621M 26.61B P/E 2024
-65.9x
P/E 2025 -29x
Enterprise Value 918M 136M 118M 110M 101M 191M 12.98B 194M 1.3B 509M 6.47B 511M 500M 21.41B EV / Sales 2024
3.33x
EV / Sales 2025 6.95x
Free-Float
62.32%
Yield 2024 *
-
Yield 2025 -
04-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25-10-16 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-09-08 Shanghai Rightongene Biotechnology's boards elects chairman RE
25-08-28 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-04-24 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-02-25 Shanghai Rightongene Biotechnology Receives 1.8 Million Yuan in Government Subsidies MT
25-02-19 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
25-02-17 Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback announced on February 29, 2024, has closed with 669,621 shares, representing 1.2% for CNY 17.02 million. CI
25-01-02 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
24-10-29 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
24-10-28 Rightongene Biotechnology's Chairman, Vice General Managers Arrested for Fraud Suspicion; Shares Down 4% MT
1 day+2.28%
1 week+10.30%
3 months-30.01%
6 months-30.88%
Current year-21.59%
1 week 18.4
Extreme 18.4
20.66
1 month 17.81
Extreme 17.81
23.34
Current year 17.81
Extreme 17.81
33.27
1 year 17.81
Extreme 17.81
36
3 years 12.38
Extreme 12.38
43.05
5 years 12.38
Extreme 12.38
86.39
10 years 12.38
Extreme 12.38
133.67
Manager TitleAgeSince
Chief Executive Officer 69 2024-07-21
Director of Finance/CFO 34 2025-01-26
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 53 2023-08-23
Chairman 69 2024-07-21
Director/Board Member 41 2019-05-12
Change 5-day change 1-year change 3-year change Capi.($)
+2.28%+10.30%-28.24%-46.23% 169M
+6.33%+9.95%+295.29%+315.15% 21.74B
-3.83%-1.14%-45.07%-29.17% 9.38B
-1.35%-4.94%+39.96%+15.20% 6.49B
-4.37%+2.16%+251.45%-24.94% 6B
-1.81%-0.93%-13.78%-15.42% 5.57B
-2.61%+0.97%-44.20% - 4.43B
+4.21%+7.67%-16.15%-29.58% 4.38B
+9.99%+1.30%+75.99%+91.71% 4.25B
-1.02%+5.24%-16.77%-40.86% 2.8B
Average +0.78%+2.08%+49.85%+26.21% 6.52B
Weighted average by Cap. +1.59%+3.43%+117.98%+108.24%

Financials

2024 2025
Net sales 242M 35.92M 31.21M 29.04M 26.68M 50.43M 3.43B 51.17M 342M 134M 1.71B 135M 132M 5.65B 177M 26.28M 22.83M 21.25M 19.52M 36.89M 2.51B 37.43M 250M 98.37M 1.25B 98.69M 96.53M 4.14B
Net income -15.76M -2.34M -2.03M -1.89M -1.74M -3.28M -223M -3.33M -22.27M -8.75M -111M -8.78M -8.58M -368M -50.38M -7.47M -6.49M -6.04M -5.55M -10.48M -712M -10.64M -71.18M -27.96M -355M -28.05M -27.43M -1.18B
Net Debt -210M -31.18M -27.09M -25.21M -23.16M -43.77M -2.97B -44.41M -297M -117M -1.48B -117M -115M -4.91B -223M -32.99M -28.66M -26.67M -24.5M -46.31M -3.15B -46.99M -314M -123M -1.57B -124M -121M -5.19B
Logo Shanghai Rightongene Biotechnology Co., Ltd.
Shanghai Rightongene Biotechnology Co Ltd is a China-based company mainly engaged in the research and development, production, sales, scientific research, and testing services of in vitro diagnostic products. The Company mainly provides self-branded molecular diagnostic reagents, scientific research services, testing services, and molecular testing equipment. The Company's main products are molecular diagnostic kits for leukemia, lymphoma, solid tumors, and infectious disease related genes. The Company's main services include providing third-party medical testing services for various medical institutions, pharmaceutical companies, individual patients, and others, as well as providing genetic testing research services for research hospitals, pharmaceutical companies, scientific research institutions, third-party testing institutions and other enterprises and institutions.
Employees
336
Date Price Change Volume
26-07-31 CN¥20.66 +2.28% 797,011
26-07-30 CN¥20.20 +0.15% 956,607
26-07-29 CN¥20.17 +4.02% 1,086,583
26-07-28 CN¥19.39 -0.67% 856,390
26-07-27 CN¥19.52 +4.22% 986,985

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 688217 Stock